$XBI $62.81 | -7.22%
Table of Contents:
Covid Updates
$AKTX -5% Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting.
$VERU +5% FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients.
Pipeline Updates
$SRNE -13% Scilex, a Sorrento Company, Highlights Safety Data From Phase 1 Trial of SP-104, a Proprietary Low Dose Naltrexone for Fibromyalgia.
$CUE -15% Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms’ Tumor 1 (WT1) - expressing cancers.
$ICPT -9% Intercept Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis.
$IRTM -11% Iterum Therapeutics Provides Regulatory Update.
$LNTH +1% Lantheus Announces Updates to the NCCN Guidelines for PSMA PET Imaging for Prostate Cancer.
$MDNA +2% Medicenna Presents Phase 1/2 ABILITY Study Data Highlighting MDNA11’s Favorable Clinical Profile at the 2022 Frontiers in Cancer Immunotherapy Meeting.
$ZYNE -13% Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting
Business Updates
$JAGX -8% TAG Investment Bankers Ltd. Issues Analyst Report on Jaguar Health
Posted by FS/DV
Kommentare